Testing effectiveness (Phase 2)Study completedNCT01172223What this trial is testingPrimary Chemotherapy in Patients With HER2-positive Early Breast CancerWho this might be right forBreast Cancer Prof Dirk Elling 81
Not applicableUnknownNCT05734950What this trial is testingBiological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast CancerWho this might be right forBreast Cancer Female Royal Marsden NHS Foundation Trust 100
Testing effectiveness (Phase 2)Ended earlyNCT01928615What this trial is testingSubcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT05069038What this trial is testingClinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine TherapyWho this might be right forBreast Cancer University of Nebraska 51
Testing effectiveness (Phase 2)Looking for participantsNCT05020860What this trial is testingCorrelation of Clinical Response to Pathologic Response in Patients With Early Breast CancerWho this might be right forBreast CancerBreast NeoplasmBreast Cancer Female+8 more Baylor Breast Care Center 185
Testing effectiveness (Phase 2)Active Not RecruitingNCT06001762What this trial is testingTRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerWho this might be right forBreast CancerEarly-stage Breast CancerHigh Risk Breast Carcinoma Dana-Farber Cancer Institute 90
Testing effectiveness (Phase 2)Study completedNCT03988036What this trial is testingA Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)Who this might be right forBreast Cancer Women's Cancer Study Group GmbH 46
Large-scale testing (Phase 3)Study completedNCT01566721What this trial is testingA Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerWho this might be right forBreast Neoplasms Hoffmann-La Roche 2,577
Early research (Phase 1)Not Yet RecruitingNCT07601620What this trial is testingEvaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast CancerWho this might be right forHER2 + Breast Cancer Shanghai Henlius Biotech 258
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225What this trial is testingPhase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label TrialWho this might be right forBreast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Not applicableNot Yet RecruitingNCT07019272What this trial is testingNeratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World StudyWho this might be right forHER2-positive Breast Cancer Hebei Medical University Fourth Hospital 170
Testing effectiveness (Phase 2)WithdrawnNCT04273555What this trial is testingMonitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR ImagingWho this might be right forHER2-positive Breast Cancer University of Alabama at Birmingham
Large-scale testing (Phase 3)UnknownNCT01093235What this trial is testingCombination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast CancerWho this might be right forBreast CancerCardiac ToxicityPerioperative/Postoperative Complications Cambridge University Hospitals NHS Foundation Trust 800
Large-scale testing (Phase 3)UnknownNCT00712140What this trial is testingTrastuzumab in Treating Women With HER2-Positive Early Breast CancerWho this might be right forBreast Cancer Warwick Medical School 4,000
Not applicableStudy completedNCT02521363What this trial is testingImplantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast CancerWho this might be right forBreast Cancer Memorial Sloan Kettering Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT00436566What this trial is testingDoxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By SurgeryWho this might be right forBreast CancerCardiac Toxicity Mayo Clinic 122
Large-scale testing (Phase 3)Study completedNCT04629846What this trial is testingStudy in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.Who this might be right forBreast Cancer Qilu Pharmaceutical Co., Ltd. 517
Not applicableLooking for participantsNCT06711068What this trial is testingAdjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target TherapyWho this might be right forHER2-positive Breast Cancer Shu Wang 8,077
Large-scale testing (Phase 3)Looking for participantsNCT05827081What this trial is testingPhase IIIb Study of Ribociclib + ET in Early Breast CancerWho this might be right forEarly Breast Cancer Novartis Pharmaceuticals 1,400
Large-scale testing (Phase 3)Looking for participantsNCT07797218What this trial is testingNeoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCWho this might be right forBreast Cancer Early Stage Breast Cancer (Stage 1-3) Shanghai Jiao Tong University School of Medicine 220